District of Columbia
CNS clinical trials in District of Columbia
33 CNS studies are recruiting participants at sites in 1 city across District of Columbia as of November 16, 2026, according to ClinicalTrials.gov.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Every District of Columbia city with a recruiting study
By research area: Depression (7), Multiple Sclerosis (7), Migraine (6), Parkinson's Disease (6), Epilepsy (3), ADHD (2), Schizophrenia (2).
Washington D.C. (33).
The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.
Depression: recently updated in District of Columbia
Basic details from each study's public record (the 12 most recently updated of 33). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
E-Mindfulness Approaches for Living After Breast Cancer
- Phase 3
- Ages 18 to 50
- All sexes
- Sponsor
- NRG Oncology
- Recruiting in
- Washington D.C.
- Registry record
- NCT06748222 · updated
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
- Phase 3
- Ages 12 to 17
- All sexes
- Sponsor
- Janssen Research & Development, LLC
- Recruiting in
- Washington D.C.
- Registry record
- NCT07227454 · updated
Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in District of Columbia on ClinicalTrials.gov.
ADHD: recently updated in District of Columbia
The Myelin Disorders Biorepository Project
- Observational
- All ages
- All sexes
- Sponsor
- Children's Hospital of Philadelphia
- Recruiting in
- Washington D.C.
- Registry record
- NCT03047369 · updated
Source: ClinicalTrials.gov. Data processed . See every ADHD study recruiting in District of Columbia on ClinicalTrials.gov.
Parkinson's disease: recently updated in District of Columbia
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Recruiting in
- Washington D.C.
- Registry record
- NCT06841354 · updated
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- Phase 3
- Ages 18 and older
- Female participants
- Sponsor
- Merck Sharp & Dohme LLC
- Recruiting in
- Washington D.C.
- Registry record
- NCT06952504 · updated
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
- Phase 3
- Ages 50 to 85
- All sexes
- Sponsor
- Hoffmann-La Roche
- Recruiting in
- Washington D.C.
- Registry record
- NCT07174310 · updated
A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease
- Phase 3
- Ages 45 to 75
- All sexes
- Sponsor
- BlueRock Therapeutics
- Recruiting in
- Washington D.C.
- Registry record
- NCT06944522 · updated
Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in District of Columbia on ClinicalTrials.gov.
Multiple sclerosis (MS): recently updated in District of Columbia
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Recruiting in
- Washington D.C.
- Registry record
- NCT03816345 · updated
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
- Observational
- Ages 18 and older
- All sexes
- Sponsor
- TG Therapeutics, Inc.
- Recruiting in
- Washington D.C.
- Registry record
- NCT06433752 · updated
Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in District of Columbia on ClinicalTrials.gov.
Epilepsy: recently updated in District of Columbia
Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- Neurona Therapeutics
- Recruiting in
- Washington D.C.
- Registry record
- NCT05135091 · updated
Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in District of Columbia on ClinicalTrials.gov.
Migraine: recently updated in District of Columbia
Dietary Intervention for Migraine Relief
- No phase
- Ages 18 to 75
- All sexes
- Sponsor
- American University
- Recruiting in
- Washington D.C.
- Registry record
- NCT07360405 · updated
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
- Phase 3
- Ages 6 to 17
- All sexes
- Sponsor
- Pfizer
- Recruiting in
- Washington D.C.
- Registry record
- NCT04649242 · updated
Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in District of Columbia on ClinicalTrials.gov.
Ask about studies in District of Columbia
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.
CNS Clinical Research does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections